MEDIA RELEASE Using Gold Nanoprobes to Unlock Your Genetic Profile

For more accurate prescription for stroke and heart patients Singapore, May 29, 2014 – A fast and cost-effective genetic test to determine the correct dosage of blood thinning drugs for the treatment of stroke, heart problems and deep vein thrombosis has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN). Using gold nanoprobes, this new technology offers personalized healthcare based on the genetic profile of the patients. IBN Executive Director Professor Jackie Y. Ying said, “Diseases caused by blood clots can be potentially fatal. Genetic testing can improve the treatment of such medical conditions. By combining our expertise in molecular diagnostics and nanotechnology, we have developed a new genetic test that can determine the appropriate drug dosage to be administered for each patient.” Blood thinning drugs or anticoagulant medication prevent clots from forming in the blood. They are used to treat stroke, irregular heartbeat and deep vein thrombosis. Warfarin is the most widely prescribed oral anticoagulant drug. But the dosage for each individual is highly variable, and the wrong dosage can cause an adverse reaction